{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed+T-Cell+Lymphoma&page=22", "query": { "condition": "Relapsed T-Cell Lymphoma", "page": 22 }, "page_size": 10 }, "pagination": { "page": 22, "page_size": 10, "total_count": 750, "total_pages": 75, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed+T-Cell+Lymphoma&page=23&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed+T-Cell+Lymphoma&page=21&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-22T08:59:29.341Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00003816", "title": "Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Chronic Myeloproliferative Disorders", "Leukemia", "Lymphoma", "Myelodysplastic Syndromes", "Myelodysplastic/Myeloproliferative Diseases", "Nonmalignant Neoplasm", "Unspecified Adult Solid Tumor, Protocol Specific", "Unspecified Childhood Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "anti-thymocyte globulin", "type": "BIOLOGICAL" }, { "name": "busulfan", "type": "DRUG" }, { "name": "carboplatin", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "melphalan", "type": "DRUG" }, { "name": "thiotepa", "type": "DRUG" }, { "name": "total-body irradiation", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "RADIATION" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "4 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "4 Years to 70 Years" }, "enrollment_count": 361, "start_date": "1998-10-19", "completion_date": "2019-07-12", "has_results": true, "last_update_posted_date": "2021-08-13", "last_synced_at": "2026-10-22T08:59:29.341Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003816" }, { "nct_id": "NCT01226472", "title": "Extension Study in Subjects Who Relapsed After Complete Response on Study KW-0761-001", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Peripheral T-cell Lymphoma", "Cutaneous T-cell Lymphoma" ], "interventions": [ { "name": "KW-0761", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Kyowa Kirin Co., Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2010-08", "completion_date": "2012-09", "has_results": true, "last_update_posted_date": "2024-04-25", "last_synced_at": "2026-10-22T08:59:29.341Z", "location_count": 1, "location_summary": "Stanford, California", "locations": [ { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01226472" }, { "nct_id": "NCT06131801", "title": "Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Hematologic Malignancy", "Leukemia", "Lymphoma", "Acute Lymphocytic Leukemia", "ALL", "Acute Myelogenous Leukemia", "AML", "Chronic Myelogenous Leukemia", "CML", "Myeloproliferative Neoplasm", "Non Hodgkin Lymphoma", "Hodgkin Lymphoma", "Diffuse Large B Cell Lymphoma", "Follicular Lymphoma", "Burkitt Lymphoma", "T-cell Lymphoma", "B Cell Lymphoma", "Peripheral T Cell Lymphoma", "Cutaneous B-Cell Lymphoma" ], "interventions": [ { "name": "1. Drug: The Venetoclax PK study is collecting bodily fluid samples (ie., whole blood and optional cerebrospinal fluid) of patients prescribed venetoclax as crushed tablets per standard of care.", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Children's Hospital Medical Center, Cincinnati", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "0 Years", "maximum_age": "38 Years", "sex": "ALL", "summary": "0 Years to 38 Years" }, "enrollment_count": 30, "start_date": "2023-11-15", "completion_date": "2027-12-01", "has_results": false, "last_update_posted_date": "2026-10-01", "last_synced_at": "2026-10-22T08:59:29.341Z", "location_count": 6, "location_summary": "Aurora, Colorado • Atlanta, Georgia • Cincinnati, Ohio + 3 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06131801" }, { "nct_id": "NCT05052528", "title": "Fludarabine and Cyclophosphamide With or Without Rituximab Before CD19 Chimeric Antigen Receptor T Cells for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent Diffuse Large B-Cell Lymphoma", "Refractory Diffuse Large B-Cell Lymphoma" ], "interventions": [ { "name": "Chimeric Antigen Receptor T-Cell Therapy", "type": "BIOLOGICAL" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine Phosphate", "type": "DRUG" }, { "name": "Rituximab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "University of California, Davis", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2021-09-17", "completion_date": "2027-12-15", "has_results": false, "last_update_posted_date": "2026-07-17", "last_synced_at": "2026-10-22T08:59:29.341Z", "location_count": 1, "location_summary": "Sacramento, California", "locations": [ { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05052528" }, { "nct_id": "NCT06788964", "title": "Loncastuximab Tesirine and Rituximab as Bridging Therapy Before Standard-of-care CAR-T Therapy in Patients With Large B-cell Lymphoma (CORAL)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Relapsed or Refractory Large B-cell Lymphoma" ], "interventions": [ { "name": "Loncastuximab Tesirine", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Utah", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 29, "start_date": "2025-08-25", "completion_date": "2030-03", "has_results": false, "last_update_posted_date": "2026-10-16", "last_synced_at": "2026-10-22T08:59:29.341Z", "location_count": 2, "location_summary": "Chapel Hill, North Carolina • Salt Lake City, Utah", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT06788964" }, { "nct_id": "NCT01088763", "title": "Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Childhood Atypical Teratoid/Rhabdoid Tumor", "Childhood Central Nervous System Choriocarcinoma", "Childhood Central Nervous System Germinoma", "Childhood Central Nervous System Mixed Germ Cell Tumor", "Childhood Central Nervous System Teratoma", "Childhood Central Nervous System Yolk Sac Tumor", "Childhood Choroid Plexus Tumor", "Childhood Craniopharyngioma", "Childhood Ependymoblastoma", "Childhood Grade I Meningioma", "Childhood Grade II Meningioma", "Childhood Grade III Meningioma", "Childhood Infratentorial Ependymoma", "Childhood Medulloepithelioma", "Childhood Mixed Glioma", "Childhood Oligodendroglioma", "Childhood Supratentorial Ependymoma", "Gonadotroph Adenoma", "Pituitary Basophilic Adenoma", "Pituitary Chromophobe Adenoma", "Pituitary Eosinophilic Adenoma", "Prolactin Secreting Adenoma", "Recurrent Childhood Acute Lymphoblastic Leukemia", "Recurrent Childhood Anaplastic Large Cell Lymphoma", "Recurrent Childhood Brain Stem Glioma", "Recurrent Childhood Central Nervous System Embryonal Tumor", "Recurrent Childhood Cerebellar Astrocytoma", "Recurrent Childhood Cerebral Astrocytoma", "Recurrent Childhood Ependymoma", "Recurrent Childhood Grade III Lymphomatoid Granulomatosis", "Recurrent Childhood Large Cell Lymphoma", "Recurrent Childhood Lymphoblastic Lymphoma", "Recurrent Childhood Medulloblastoma", "Recurrent Childhood Pineoblastoma", "Recurrent Childhood Small Noncleaved Cell Lymphoma", "Recurrent Childhood Spinal Cord Neoplasm", "Recurrent Childhood Subependymal Giant Cell Astrocytoma", "Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor", "Recurrent Childhood Visual Pathway and Hypothalamic Glioma", "Recurrent Childhood Visual Pathway Glioma", "Recurrent Pituitary Tumor", "Recurrent/Refractory Childhood Hodgkin Lymphoma", "T-cell Childhood Acute Lymphoblastic Leukemia", "T-cell Large Granular Lymphocyte Leukemia", "TSH Secreting Adenoma", "Unspecified Childhood Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "gamma-secretase/Notch signalling pathway inhibitor RO4929097", "type": "DRUG" }, { "name": "diagnostic laboratory biomarker analysis", "type": "OTHER" }, { "name": "pharmacological study", "type": "OTHER" }, { "name": "dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "21 Years", "sex": "ALL", "summary": "1 Year to 21 Years" }, "enrollment_count": 129, "start_date": "2010-03", "completion_date": "2011-05", "has_results": false, "last_update_posted_date": "2014-11-05", "last_synced_at": "2026-10-22T08:59:29.341Z", "location_count": 11, "location_summary": "Palo Alto, California • Stanford, California • Chicago, Illinois + 8 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01088763" }, { "nct_id": "NCT01184885", "title": "A Pilot Study to Determine the Safety and Tolerability of Sirolimus Given With Hyper-CVAD Chemotherapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Lymphoid Malignancies (New or Relapsed)", "Acute Lymphoblastic Leukemia", "Burkitt Lymphoma", "Lymphoblastic Lymphoma", "Mantle Cell Lymphoma", "Adult T-cell Leukemia/Lymphoma" ], "interventions": [ { "name": "Hyper-CVAD", "type": "DRUG" }, { "name": "Sirolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 7, "start_date": "2010-07", "completion_date": "2013-04", "has_results": true, "last_update_posted_date": "2025-05-04", "last_synced_at": "2026-10-22T08:59:29.341Z", "location_count": 2, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01184885" }, { "nct_id": "NCT05544968", "title": "Anti-CD30 biAb-AATC in Patients With Relapsed/Refractory CD30 Positive Hematopoietic Malignancies", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hodgkin Disease", "CD30-Positive Diffuse Large B-Cell Lymphoma", "CD30+ Anaplastic Large Cell Lymphoma", "CD30+ Pleomorphic Large T-Cell Cutaneous Lymphoma", "CD30+ Immunoblastic Large T-Cell Cutaneous Lymphoma", "Leukemia", "Lymphoma" ], "interventions": [ { "name": "anti-CD30 Bispecific Antibody-armed anti-CD3-Activated Autologous T-cells (CD30 biAb-AATC)", "type": "DRUG" }, { "name": "GM-CSF", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Medical College of Wisconsin", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 42, "start_date": "2026-03-04", "completion_date": "2029-07", "has_results": false, "last_update_posted_date": "2026-04-03", "last_synced_at": "2026-10-22T08:59:29.341Z", "location_count": 1, "location_summary": "Milwaukee, Wisconsin", "locations": [ { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT05544968" }, { "nct_id": "NCT01378871", "title": "A Phase II Study Of Imtox-25 In Adults With Refractory/Relapsed Cd25 Positive Adult T Cell Leukemia/Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adult T Cell Leukemia", "Adult T Cell Lymphoma" ], "interventions": [ { "name": "IMTOX-25", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amit Verma", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2010-09", "completion_date": "2013-01", "has_results": true, "last_update_posted_date": "2023-06-09", "last_synced_at": "2026-10-22T08:59:29.341Z", "location_count": 7, "location_summary": "The Bronx, New York", "locations": [ { "city": "The Bronx", "state": "New York" }, { "city": "The Bronx", "state": "New York" }, { "city": "The Bronx", "state": "New York" }, { "city": "The Bronx", "state": "New York" }, { "city": "The Bronx", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01378871" }, { "nct_id": "NCT06090864", "title": "ATLCAR.CD30.CCR4 for CD30+ HL ATLCAR.CD30.CCR4 Cells", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Hodgkin Lymphoma", "Relapse", "Refractory" ], "interventions": [ { "name": "Chemotherapy", "type": "DRUG" }, { "name": "Cell infusion", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "UNC Lineberger Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 31, "start_date": "2024-04-25", "completion_date": "2033-07-01", "has_results": false, "last_update_posted_date": "2026-08-06", "last_synced_at": "2026-10-22T08:59:29.341Z", "location_count": 1, "location_summary": "Chapel Hill, North Carolina", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT06090864" } ] }